(19)
(11) EP 1 385 993 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.09.2011 Bulletin 2011/38

(45) Mention of the grant of the patent:
20.04.2011 Bulletin 2011/16

(21) Application number: 01995497.3

(22) Date of filing: 10.12.2001
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
(86) International application number:
PCT/US2001/047839
(87) International publication number:
WO 2002/046475 (13.06.2002 Gazette 2002/24)

(54)

METHOD OF DETECTING AND TREATING TUBEROUS SCLEROSIS COMPLEX ASSOCIATED DISORDERS

VERFAHREN ZUR BESTIMMUNG UND BEHANDLUNG VON TUBERÖSE-SKLEROSE KOMPLEX ASSOZIIERTEN ERKRANKUNGEN

PROCEDE DE DETECTION ET DE TRAITEMENT DE PATHOLOGIES ASSOCIEES AU SYNDROME DE LA SCLEROSE TUBEREUSE

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

(30) Priority: 08.12.2000 US 254268 P

(43) Date of publication of application:
04.02.2004 Bulletin 2004/06

(73) Proprietor: Celldex Therapeutics, Inc.
Needham, MA 02494 (US)

(72) Inventors:
  • RASTELLI, Luca
    Guilford, CT 06437 (US)
  • GOULD-ROTHBERG, Bonnie
    Guilford, CT 06437 (US)
  • MURPHEY, Ryan
    New Haven, CT 06511 (US)

(74) Representative: Crump, Julian Richard John et al
Mintz Levin Cohn Ferris Glovsky & Popeo Intellectual Property LLP Alder Castle 10 Noble Street
London EC2V 7JX
London EC2V 7JX (GB)


(56) References cited: : 
WO-A-00/64941
WO-A-95/18225
 WO-A-00/64941
WO-A-95/18225
   
  • DATABASE EMBL [Online] XP002238412 Database accession no. ak089421 & CARNINCI P ET AL: "HIGH-EFFICIENCY FULL-LENGTH CDNA CLONING" METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC, SAN DIEGO, CA, US, vol. 303, 1999, pages 19-44, XP001022979 ISSN: 0076-6879
  • DATABASE GENBANK EMBL; Mus musculus mRNA 7 January 2000 (2000-01-07), BACHNER,D: XP002365779 Database accession no. aj251685
  • FANG JIN ET AL: "Identification of the increased expression of monocyte chemoattractant protein-1, cathepsin S, UPIX-1, and other genes in dystrophin-deficient mouse muscles by suppression subtractive hybridization" JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 79, no. 1, 19 July 2000 (2000-07-19), pages 164-172, XP002365777 ISSN: 0730-2312
  • CHEADLE J P ET AL: "MOLECULAR GENETIC ADVANCES IN TUBEROUS SCLEROSIS" HUMAN GENETICS, BERLIN, DE, vol. 107, no. 2, August 2000 (2000-08), pages 97-114, XP000965751 ISSN: 0340-6717
  • WETERMAN M A J ET AL: "NMB, A NOVEL GENE, IS EXPRESSED IN LOW-METASTATIC HUMAN MELANOMA CELL LINES AND XENOGRAFTS" INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 60, no. 1, 3 January 1995 (1995-01-03), pages 73-81, XP002044250 ISSN: 0020-7136
  • DATABASE EMBL [Online] Database accession no. ak089421 XP002238412 & CARNINCI P ET AL: "HIGH-EFFICIENCY FULL-LENGTH CDNA CLONING" METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC, SAN DIEGO, CA, US, vol. 303, 1999, pages 19-44, XP001022979 ISSN: 0076-6879
  • POLLACK ET AL: "Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targetin GPNMB" CANCER CHEMOTHER PHARMACOL, vol. 60, 2007, pages 423-435,
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).